N-terminal Prohormone Brain Natriuretic Peptide Plasma Levels in Heart Failure Are Affected Both Directly and Indirectly by Carvedilol

Abstract

N-terminal prohormone brain natriuretic peptide (NT Pro BNP) is a sensitive marker of left ventricular function in patients with heart failure. The influence of carvedilol on NT Pro BNP plasma levels was analyzed in 21 heart failure patients. Blood samples were taken before administration and after 12 months of treatment with low-dose carvedilol. Peak oxygen consumption did not change after carvedilol treatment, left ventricular ejection fraction improved (P < .005) in 11 patients (52%), did not change in 9 (43%), and decreased in 1 (5%). In patients where left ventricular ejection fraction improved, NT Pro BNP tended to decrease; however, in patients without improvement, NT Pro BNP increased at follow-up. A correlation exists between magnitude of change in BNP and magnitude of improvement in ventricular function during carvedilol therapy. Patients without noticeable changes in left ventricular ejection fraction with a low to moderate carvedilol dosage show an increase in NT Pro BNP plasma levels.

Keywords

heart failure exercise natriuretic peptides echocardiography cardiopulmonary exercise test carvedilol

Get full access to this article

View all access options for this article.

References

CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial . Lancet. 1999;353:9-13.

MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.

Packer M. , Bristow MR , Cohn JN , et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;1349-1355.

Azuma A. , Matsuo A. , Nakamura T. , et al. Improved survival in idiopathic cardiomyopathy in the 1990s. Jpn Circ J. 1999;63:333-338.

Packer M. , Fowler MB , Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194-2199.

Mukoyama M. , Nakao K. , Hosoda K. , et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-1412.

Yasue H. , Yoshimura M. , Sumida H. , et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.

Yamamoto K. , Burnett JC Jr , Jougasaki M. , et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy . Hypertension. 1996;28:988-994.

Tsutamoto T. , Wada A. , Maeda K. , et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation . 1997;96:509-516.

10.

Richards AM , Nicholls MG , Yandle TG , et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation . 1998;97:1921-1929.

11.

Nakaoka H. , Kitahara Y. , Amano M. , et al. Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension. 1987;10:221-225.

12.

Yoshimoto T. , Naruse M. , Tanabe A. , et al. Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology . 1998;139:81-88.

13.

Luchner A. , Burnett JC Jr , Jougasaki M. , Hense HW , Riegger GA , Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Col Cardiol. 1998;32:1839-1844.

14.

Tanaka M. , Ishizaka Y. , Ishiyama Y. , et al. Chronic effect of beta-adrenoceptor blockade on plasma levels of brain natriuretic peptide during exercise in essential hypertension. Hypertens Res. 1996;19:239-245.

15.

Riley M. , Northridge DB , Henderson E. , Stanford CF , Nicholls DP , Dargie HJ The use of an exponential protocol for bicycle and treadmill exercise testing in patients with chronic cardiac failure. Eur Heart J. 1992;13:1363-1367.

16.

Wu AH , Smith A. , Wieczorek S. , et al. Biological variation for N-terminal pro and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628-631.

17.

Fujimura M. , Yasumara Y. , Ishida Y. , et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail. 2000;6:3-10.

18.

Kawai K. , Hata K. , Takaoka H. , Kawai H. , Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J. 2001 ;141:925-932.

19.

Knight EL , Fish LC , Kiely DK , Marcantonio ER , Davis KM , Minaker KL Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. JAMA. 1992;267:2625-2629.

20.

Christensen G. , Aksnes G. , Ilebekk A. , et al. Release of atrial natriuretic factor during selective cardiac alpha- and beta-adrenergic stimulation, intracoronary Ca2+ infusion, and aortic constriction in pigs. Circ Res. 1991;68:638-644.

21.

22.

Nakaoka H. , Kitahara Y. , Amano M. , et al. Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension. 1987;10:221-225.

23.

24.

Luchner A. , Burnett JCJ , Jougasaki M. , et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Col Cardiol. 1998;32:1839-1844.

25.

Marie PY , Mertes PM , Hassan-Sebbag N. , et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Col Cardiol. 2004;43:353-359.